Replimune Reports Fiscal Q2 2027 Net Loss of $57.1 Million
The company reported a $57.1 million net loss for the quarter ended September 30, 2026, compared with $83.1 million a year earlier. Cash and cash equivalents totaled $307.8 million at quarter-end.
Story updates
11:19:43 AM UTC
SquawkNews
*--Earnings Flash (REPL) Replimune Posts Fiscal Q2 Net Loss $0.54 a Share, vs. FactSet Est of $0.71 Loss
11:31:42 AM UTC
SquawkNews
Replimune Group reported no product revenue in the third quarter of 2026, as commercial sales of TUDRIQEV began in October. Net loss narrowed to $57.1M from $83.1M a year earlier, while diluted loss per share was $0.54 versus $0.9.Financial HighlightsBusiness HighlightsOriginal SEC Filing: Replimun…
Replimune reported a net loss of $57.1 million for the fiscal second quarter ended September 30, 2026, compared with $83.1 million a year earlier. The company had $307.8 million in cash and cash equivalents at quarter-end. TUDRIQEV became commercially available in the U.S. in October for advanced m…